Catalyst Pharmaceuticals (NASDAQ:CPRX) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a research report report published on Friday morning,Benzinga reports. They currently have a $35.00 target price on the biopharmaceutical company’s stock.

CPRX has been the topic of several other research reports. Truist Financial raised their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Robert W. Baird started coverage on shares of Catalyst Pharmaceuticals in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $28.00 target price for the company. Bank of America reiterated a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Finally, StockNews.com lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 11th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $32.00.

Catalyst Pharmaceuticals Stock Up 5.7 %

CPRX stock opened at $22.89 on Friday. Catalyst Pharmaceuticals has a twelve month low of $14.47 and a twelve month high of $24.64. The company has a market cap of $2.73 billion, a P/E ratio of 19.40, a price-to-earnings-growth ratio of 3.31 and a beta of 0.80. The business’s fifty day moving average is $22.21 and its 200-day moving average is $21.40.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the transaction, the insider now owns 686,996 shares in the company, valued at approximately $15,065,822.28. This represents a 6.78 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 11.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Creative Planning raised its position in Catalyst Pharmaceuticals by 26.9% in the 3rd quarter. Creative Planning now owns 12,724 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 2,699 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Catalyst Pharmaceuticals by 11.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 20,017 shares of the biopharmaceutical company’s stock valued at $398,000 after purchasing an additional 1,989 shares during the last quarter. DekaBank Deutsche Girozentrale raised its holdings in shares of Catalyst Pharmaceuticals by 48.6% in the third quarter. DekaBank Deutsche Girozentrale now owns 183,376 shares of the biopharmaceutical company’s stock valued at $3,532,000 after purchasing an additional 60,000 shares during the last quarter. Summit Global Investments lifted its position in shares of Catalyst Pharmaceuticals by 2.6% in the third quarter. Summit Global Investments now owns 77,292 shares of the biopharmaceutical company’s stock worth $1,537,000 after purchasing an additional 1,923 shares in the last quarter. Finally, CWA Asset Management Group LLC acquired a new position in Catalyst Pharmaceuticals during the third quarter worth $534,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.